US006011049A

United States Patent [19]

Whitcomb

[11] **Patent Number: 6,011,049**

[45] **Date of Patent: Jan. 4, 2000**

[54] **COMBINATIONS FOR DIABETES**

[75] Inventor: **Randall Wayne Whitcomb**, Ann Arbor, Mich.

[73] Assignee: **Warner-Lambert Company**, Morris Plains, N.J.

[21] Appl. No.: **09/189,132**

[22] Filed: **Nov. 9, 1998**

Related U.S. Application Data

[63] Continuation-in-part of application No. 08/970,057, Nov. 13, 1997, Pat. No. 5,859,037

[60] Provisional application No. 60/038,224, Feb. 19, 1997.

[51] **Int. Cl.**[7] **A61K 31/44**; A61K 31/425; A61K 31/175; A61K 31/155

[52] **U.S. Cl.** **514/369**; 514/342; 514/593; 514/635; 514/866

[58] **Field of Search** 514/342, 369, 514/593, 635, 866

[56] **References Cited**

FOREIGN PATENT DOCUMENTS

0749751	12/1996	European Pat. Off. .
0753298	1/1997	European Pat. Off. .
9609823	4/1996	WIPO .

OTHER PUBLICATIONS

PCT International Search Report, PCT/US97/21996.

Oakes, et al., *Diabetes*, vol. 13:1203, 1994, A New Antidiabetic Agent, BRL 49653, Reduces Lipid Availability and Improves Insulin Action and Glucoregulation in the Rat.

Hulin, et al, *Current Pharmaceutical Design* 2:85–102, 1996, The Glitazone Family of Antidiabetic Agents.

Groop, M.D., *Diabetes Care*, 15:737–754, 1992, Sulfonylureas in NIDDM.

Nakano, et al., *CS–045*, Clinical Evaluation of a New Oral Hypoglycemic Drug, CS–045, on Daily Profile of Blood Glucose in Patients with Non–Insulin Dependent Diabetes Mellitus (1993).

Company News On–Call, 1–3, 1997 Rezulin® (troglitazone) Receives FDA Marketing Clearance for use as Either Initial or Combination Therapy for Type 2 Diabetes.

Spencer, et al., *Drugs*, vol. 54:89–101, 1997, Troglitazone.

Yamasaki, et al., *The Tokohu Journal of Experimental Medicine*, vol. 183:173–183, 1997, Pioglitazone (AD–4833) Ameliorates Insulin Resistance in Patients with NIDDM.

Iwamoto, et al., *Diabetic Medicine*, vol. 13:365–370, 1996, Effect of Combination Therapy of Troglitazone and Sulphonylureas in Patients with Type 2 Diabetes Who Were Poorly Controlled by Sulphonylurea Alon.

Bressler & Johnson., *Drugs& Aging*, vol. 9:418–437, 1996, Oral Antidiabetic Drug Use in the Elderly.

Okaka, et al., *Chemical Abstracts*, vol. 126, No. 20, 1997, Abstract No. 258925, Antidiabetic Effects of Pioglitzone HCL Alone or in Combination with Insulin or Sylfonylurea in Diabetic Animals.

De Souza, et al., *Diabetes*, vol. 44:984–991, 1995, Insulin Secretory Defect in Zucker fa/fa Ratsis Improved by Ameliorating Insulin Resistance.

Primary Examiner—Kimberly Jordan

Attorney, Agent, or Firm—Charles W. Ashbrook

[57] **ABSTRACT**

Combinations of a glitazone antidiabetic agent and a biguanide antidiabetic agent, and optionally a sulfonylurea antidiabetic agent, are useful for treating diabetes mellitus and improving glycemic control.

16 Claims, 12 Drawing Sheets